<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1127</article-id><article-id pub-id-type="doi">10.17816/ACEN.1127</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Glymphatic System Assessment Using DTI-ALPS in Age-Dependent Neurodegenerative Diseases</article-title><trans-title-group xml:lang="ru"><trans-title>Оценка глимфатической системы методом DTI-ALPS при возраст-зависимых нейродегенеративных заболеваниях</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8062-0784</contrib-id><name-alternatives><name xml:lang="en"><surname>Liaskovik</surname><given-names>Alina A.</given-names></name><name xml:lang="ru"><surname>Лясковик</surname><given-names>Алина Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>postgraduate student, Radiology department, Institute of Clinical and Preventive Neurology</p></bio><bio xml:lang="ru"><p>аспирант отдела лучевой диагностики Института клинической и профилактической неврологии </p></bio><email>lyaskovik@neurology.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5539-245X</contrib-id><name-alternatives><name xml:lang="en"><surname>Konovalov</surname><given-names>Rodion N.</given-names></name><name xml:lang="ru"><surname>Коновалов</surname><given-names>Родион Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), senior researcher, Radiology department, Institute of Clinical and Preventive Neurology</p></bio><bio xml:lang="ru"><p>канд. мед. наук, с. н. с. отдела лучевой диагностики Института клинической и профилактической неврологии</p></bio><email>krn_74@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7214-583X</contrib-id><name-alternatives><name xml:lang="en"><surname>Shpilyukova</surname><given-names>Yulia A.</given-names></name><name xml:lang="ru"><surname>Шпилюкова</surname><given-names>Юлия Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), researcher, 5<sup>th</sup> Neurological department with DNA laboratory, Institute of Clinical and Preventive Neurology</p></bio><bio xml:lang="ru"><p>канд. мед. наук, врач-невролог, н. с. 5-го неврологического отделения Института клинической и профилактической неврологии </p></bio><email>jshpilyukova@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-9148-0203</contrib-id><name-alternatives><name xml:lang="en"><surname>Nevzorova</surname><given-names>Kseniya V.</given-names></name><name xml:lang="ru"><surname>Невзорова</surname><given-names>Ксения Васильевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>postgraduate student, 5<sup>th</sup> Neurological department with DNA laboratory, Institute of Clinical and Preventive Neurology</p></bio><bio xml:lang="ru"><p>аспирант 5-го неврологического отделения Института клинической и профилактической неврологии</p></bio><email>nevzorova.k.v@neurology.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3843-6435</contrib-id><name-alternatives><name xml:lang="en"><surname>Moskalenko</surname><given-names>Anna N.</given-names></name><name xml:lang="ru"><surname>Москаленко</surname><given-names>Анна Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>postgraduate student, 5<sup>th</sup> Neurological department with DNA laboratory, Institute of Clinical and Preventive Neurology</p></bio><bio xml:lang="ru"><p>аспирант 5-го неврологического отделения Института клинической и профилактической неврологии</p></bio><email>moskalenko@neurology.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8070-7644</contrib-id><name-alternatives><name xml:lang="en"><surname>Fedotova</surname><given-names>Ekaterina Yu.</given-names></name><name xml:lang="ru"><surname>Федотова</surname><given-names>Екатерина Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), leading researcher, Head, 5<sup>th</sup> Neurological department with DNA laboratory, Institute of Clinical and Preventive Neurology</p></bio><bio xml:lang="ru"><p>д-р мед. наук, в. н. с., зав. 5-м неврологическим отделением Института клинической и профилактической неврологии </p></bio><email>ekfedotova@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3820-4554</contrib-id><name-alternatives><name xml:lang="en"><surname>Krotenkova</surname><given-names>Marina V.</given-names></name><name xml:lang="ru"><surname>Кротенкова</surname><given-names>Марина Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med), Head, Radiology department, Institute of Clinical and Preventive Neurology</p></bio><bio xml:lang="ru"><p>д-р мед. наук, зав. отделом лучевой диагностики Института клинической и профилактической неврологии</p></bio><email>krotenkova_mrt@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Center of Neurology</institution></aff><aff><institution xml:lang="ru">Научный центр неврологии</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-10-03" publication-format="electronic"><day>03</day><month>10</month><year>2024</year></pub-date><volume>18</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>42</fpage><lpage>49</lpage><history><date date-type="received" iso-8601-date="2024-04-26"><day>26</day><month>04</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-06-21"><day>21</day><month>06</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Liaskovik A.A., Konovalov R.N., Shpilyukova Y.A., Nevzorova K.V., Moskalenko A.N., Fedotova E.Y., Krotenkova M.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Лясковик А.А., Коновалов Р.Н., Шпилюкова Ю.А., Невзорова К.В., Москаленко А.Н., Федотова Е.Ю., Кротенкова М.В.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Liaskovik A.A., Konovalov R.N., Shpilyukova Y.A., Nevzorova K.V., Moskalenko A.N., Fedotova E.Y., Krotenkova M.V.</copyright-holder><copyright-holder xml:lang="ru">Лясковик А.А., Коновалов Р.Н., Шпилюкова Ю.А., Невзорова К.В., Москаленко А.Н., Федотова Е.Ю., Кротенкова М.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/1127">https://annaly-nevrologii.com/pathID/article/view/1127</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> Dysfunction of the glymphatic system glymphatic system of the brain is considered a pathogenetic factor in some age-dependent neurodegenerative diseases, including Alzheimer's disease (AD), dementia with Lewy bodies (DLB), Parkinson's disease (PD), and normal pressure hydrocephalus (NPH). The innovative method for calculating DTI-ALPS (Diffusion Tensor Image Analysis ALong the Perivascular Space) allows non-invasive assessment of the glymphatic system status using magnetic resonance imaging (MRI).</p> <p>The <bold>aim</bold> of the study is to compare DTI-ALPS in patients with AD, DLB, PD, and NPH and to evaluate its potential use as a biomarker of the glymphatic system status in these diseases.</p> <p><bold>Materials and methods.</bold> The study included 116 subjects: 32 patients with AD, 15 patients with DLB, 31 patients with PD, 11 patients with NPH, and 27 healthy volunteers. Cognitive testing was performed for patients in the main groups using the Montreal Cognitive Assessment (MoCA) score. All subjects underwent diffusion tensor imaging (DTI) of the brain. DTI-ALPS was then calculated.</p> <p><bold>Results.</bold> DTI-ALPS index significantly differed across groups (<italic>p</italic> &lt; 0.001). Patients with AD, DLB, and NPH had a significantly lower DTI-ALPS index on both sides compared to the PD group and healthy volunteers (<italic>p</italic> &lt; 0.01). Analysis of the entire sample showed a direct correlation between MoCA score and DTI-ALPS index (<italic>p</italic> &lt; 0.05).</p> <p><bold>Conclusion.</bold> This is the first comparison of DTI-ALPS across such a broad range of age-dependent neurodegenerative diseases. Since our DTI-ALPS results were comparable to previously reported data, we believe that this parameter can be used as an indirect marker of the glymphatic system status.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Дисфункция глимфатической системы мозга считается одним из патогенетических факторов некоторых возраст-зависимых нейродегенеративных заболеваний, таких как болезнь Альцгеймера (БА), деменция с тельцами Леви (ДТЛ), болезнь Паркинсона (БП) и нормотензивная гидроцефалия (НТГ). Инновационный метод расчёта индекса DTI-ALPS (диффузионно-тензорные изображения с оценкой периваскулярных пространств) позволяет неинвазивно оценивать состояние глимфатической системы посредством магнитно-резонансной томографии.</p> <p><bold>Цель исследования</bold> — сравнить результаты показателя DTI-ALPS у пациентов с БА, ДТЛ, БП и НТГ, а также оценить возможность его использования в качестве биомаркера состояния глимфатической системы при этих нозологиях.</p> <p><bold>Материалы и методы.</bold> В исследовании приняли участие 116 человек: 32 пациента с БА, 15 пациентов с ДТЛ, 31 пациент с БП, 11 пациентов с НТГ и 27 здоровых добровольцев. Пациентам основных групп проводили когнитивное тестирование с использованием Монреальской шкалы оценки когнитивных функций. Всем испытуемым была проведена магнитно-резонансная томография головного мозга в режиме диффузионно-тензорной томографии с последующим вычислением индекса DTI-ALPS.</p> <p><bold>Результаты.</bold> Значения индекса DTI-ALPS значимо различались между группами (<italic>p</italic> &lt; 0,001). Пациенты с БА, ДТЛ и НТГ имели значимо более низкий индекс DTI-ALPS с обеих сторон по сравнению с группой БП и здоровыми добровольцами (<italic>p</italic> &lt; 0,01). Анализ всей выборки выявил прямую корреляцию между баллом по Монреальской шкале оценки когнитивных функций и значениями DTI-ALPS (<italic>p</italic> &lt; 0,05).</p> <p><bold>Заключение.</bold> Сравнение значений индекса DTI-ALPS среди такого широкого спектра возраст-зависимых нейродегенеративных заболеваний было проведено впервые. Учитывая, что полученные значения DTI-ALPS сопоставимы с ранее опубликованными данными, мы полагаем, что предложенный метод может быть использован в качестве косвенного маркера состояния глимфатической системы.</p></trans-abstract><kwd-group xml:lang="en"><kwd>glymphatic system</kwd><kwd>diffusion tensor imaging</kwd><kwd>magnetic resonance imaging</kwd><kwd>neurodegenerative diseases</kwd><kwd>cognitive impairment</kwd><kwd>Alzheimer's disease</kwd><kwd>Lewy body dementia</kwd><kwd>Parkinson's disease</kwd><kwd>normal pressure hydrocephalus</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>глимфатическая система</kwd><kwd>диффузионно-тензорные изображения</kwd><kwd>магнитно-резонансная томография</kwd><kwd>нейродегенеративные заболевания</kwd><kwd>когнитивные нарушения</kwd><kwd>болезнь Альцгеймера</kwd><kwd>деменция с тельцами Леви</kwd><kwd>болезнь Паркинсона</kwd><kwd>нормотензивная гидроцефалия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Erkkinen M.G., Kim M.O., Geschwind M.D. Clinical neurology and epidemiology of the majorneurodegenerative diseases. Cold Spring Harb. Perspect. Biol. 2018;10(4):a033118. DOI: 10.1101/cshperspect.a033118</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>WHO. Global Status Report on the Public Health Response to Dementia. Geneva; 2021. 137 p.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Iliff J., Wang M., Liao Y. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl. Med. 2012;4(147):147ra111. DOI: 10.1126/scitranslmed.3003748</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Jessen N.A., Munk A.S., Lundgaard I. et al. The glymphatic system: a beginner's guide. Neurochem. Res. 2015;40(12):2583–2599. DOI: 10.1007/s11064-015-1581-6</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Buccellato F.R., D'Anca M., Serpente M. et al. The role of glymphatic system in Alzheimer's and Parkinson's disease pathogenesis. Biomedicines. 2022;10(9):2261. DOI: 10.3390/biomedicines10092261</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Peng S., Liu J., Liang C. et al. Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders. Neurobiol. Dis. 2023;179:106035. DOI: 10.1016/j.nbd.2023.106035</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Reeves B.C., Karimy J.K., Kundishora A.J. et al. Glymphatic system impairment in Alzheimer's disease and idiopathic normal pressure hydrocephalus. Trends. Mol. Med. 2020;26(3):285–295. DOI: 10.1016/j.molmed.2019.11.008</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Harrison I.F., Ismail O., Machhada A. et al. Impaired glymphatic function and clearance of tau in an Alzheimer's disease model. Brain. 2020;143(8):2576 –2593. DOI: 10.1093/brain/awaa179</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Zhang Y., Zhang C., He X.Z. et al. Interaction between the glymphatic system and α-synuclein in Parkinson's disease. Mol. Neurobiol. 2023;60(4):2209–2222. DOI: 10.1007/s12035-023-03212-2</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Buongiorno M., Marzal C., Fernandez M. et al. Altered sleep and neurovascular dysfunction in alpha-synucleinopathies: the perfect storm for glymphatic failure. Front. Aging Neurosci. 2023;15:1251755. DOI: 10.3389/fnagi.2023.1251755</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Rasmussen M.K., Mestre H., Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurol. 2018;17(11):1016–1024. DOI: 10.1016/S1474-4422(18)30318-1</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Takizawa K., Matsumae M., Hayashi N. et al. The choroid plexus of the lateral ventricle as the origin of CSF pulsation is questionable. Neurol. Med. Chir. (Tokyo). 2018;58(1):23–31. DOI: 10.2176/nmc.oa.2017-0117</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Taoka T., Masutani Y., Kawai H. et al. Evaluation of glymphatic system activity with the diffusion MR technique: diffusion tensor image analysis along the perivascular space (DTI-ALPS) in Alzheimer’s disease cases. Jpn. J. Radiol. 2017;35(4):172–178. DOI: 10.1007/s11604-017-0617-z</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>McKhann G.M., Knopman D.S., Chertkow H. et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging — Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263–269. DOI: 10.1016/j.jalz.2011.03.005</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Nasreddine Z.S., Phillips N.A., Bédirian V. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 2005;53(4):695–699. DOI: 10.1111/j.1532-5415.2005.53221.x</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>McKeith I.G., Boeve B.F., Dickson D.W. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100. DOI: 10.1212/WNL.0000000000004058</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427–442. DOI: 10.1212/wnl.17.5.427</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Postuma R.B., Berg D., Stern M. et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov. Disord. 2015;30(12):1591–1601. DOI: 10.1002/mds.26424</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Relkin N., Marmarou A., Klinge P. et al. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery. 2005;57(3 Suppl):S4–S16. DOI: 10.1227/01.neu.0000168185.29659.c5</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12(3):189–198. DOI: 10.1016/0022-3956(75)90026-6</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Yeh F.C., Panesar S., Fernandes D. et al. Population-averaged atlas of the macroscale human structural connectome and its network topology. Neuroimage. 2018;178:57–68. DOI: 10.1016/j.neuroimage.2018.05.027</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Liang T., Chang F., Huang Z. et al. Evaluation of glymphatic system activity by diffusion tensor image analysis along the perivascular space (DTI-ALPS) in dementia patients. Br. J. Radiol. 2023;96(1146):20220315. DOI: 10.1259/bjr.20220315</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Williams B.W., Mack W., Henderson V.W. Boston naming test in Alzheimer's disease. Neuropsychologia. 1989;27(8):1073–1079. DOI: 10.1016/0028-3932(89)90186-3</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Wechsler D. Wechsler adult intelligence scale. San Antonio;1997.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Tombaugh T.N. Trail Making Test A and B: normative data stratified by age and education. Arch. Clin. Neuropsychol. 2004;19(2):203–214. DOI: 10.1016/S0887-6177(03)00039-8</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Zhang X., Wang Y., Jiao B. et al. Glymphatic system impairment in Alzheimer's disease: associations with perivascular space volume and cognitive function. Eur. Radiol. 2024;24(2):1314–1323. DOI: 10.1007/s00330-023-10122-3</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Shen T., Yue Y., Ba F. et al. Diffusion along perivascular spaces as marker for impairment of glymphatic system in Parkinson's disease. NPJ Parkinsons Dis. 2022;8(1):174. DOI: 10.1038/s41531-022-00437-1</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Bae Y.J., Kim J.M., Choi B.S. et al. Glymphatic function assessment in Parkinson's disease using diffusion tensor image analysis along the perivascular space. Parkinsonism Relat. Disord. 2023;114:105767. DOI: 10.1016/j.parkreldis.2023.105767</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Bae Y.J., Choi B.S., Kim J.M. et al. Altered glymphatic system in idiopathic normal pressure hydrocephalus. Parkinsonism Relat. Disord. 2021;82:56–60. DOI: 10.1016/j.parkreldis.2020.11.009</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Georgiopoulos C., Tisell A., Holmgren R.T. et al. Noninvasive assessment of glymphatic dysfunction in idiopathic normal pressure hydrocephalus with diffusion tensor imaging. J. Neurosurg. 2023;140(3):612–620. DOI: 10.3171/2023.6.JNS23260</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Ringstad G. Glymphatic imaging: a critical look at the DTI-ALPS index. Neuroradiology. 2024;66(2):157–160. DOI: 10.1007/s00234-023-03270-2</mixed-citation></ref></ref-list></back></article>
